Taken together, these results demonstrate that PKM2 loss results in amplification of PPP activity, and that PPP agonism phenocopies the results of PKM2 loss both in vitro and in vivo, with enhanced generation of TCF1high progenitor cells responsive to PD-1 blockade resulting in better anti-tumor immunity. Here, PKM is linked to neoplasm.